Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Topic or Issue
Home Search/Browse Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 27, No 15S (May 20 Supplement), 2009: 1
© 2009 American Society of Clinical Oncology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rustin, G. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rustin, G. J.

Abstract

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

G. J. Rustin, M. E. van der Burg on behalf of MRC and EORTC collaborators

Mount Vernon Cancer Centre, Middlesex, United Kingdom; Erasmus MC University Medical Center, Rotterdam, Netherlands

1

The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

No significant financial relationships to disclose.

Abstract presentation from the 2009 ASCO Annual Meeting




About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
HighWire Press HighWire Press™ assists in the publication of JCO Online